A Review of the Efficacy, Safety, and Cost‐Effectiveness of COX‐2 Inhibitors for Africa and the Middle East Region

  title={A Review of the Efficacy, Safety, and Cost‐Effectiveness of COX‐2 Inhibitors for Africa and the Middle East Region},
  author={Anwar Z Zeidan and Bashar Al Sayed and Naceur Bargaoui and Mourad Djebbar and Malik Djennane and Royden Donald and Khamis El Deeb and Raed A Joudeh and Abdullah Bin Nabhan and Stephan A. Schug},
  journal={Pain Practice},
Abstract:  Despite an increasingly sophisticated understanding of pain mechanisms, acute and chronic pain remain undertreated throughout the world. This situation reflects the large gap that exists between evidence and practice in pain management and is typified by inappropriate use of nonsteroidal anti‐inflammatory drugs (NSAIDs). The scientific evidence around these drugs continues to expand at a high rate, yet physicians are often unaware of best practice. To address this gap among… 

NSAIDs for musculoskeletal pain management:current perspectives and novel strategies to improve safety.

Recommendations for the appropriate use of NSAIDs are reviewed, risk/benefit analysis is incorporated into decision making, and the efficacy and safety of recently approved and emerging NSAID formulations are evaluated.

Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines.

These guidelines are intended to provide a systematic and standardized approach to this complex and difficult arena of practice, while recognizing that every clinical situation is unique.

A review on COX and their inhibitors: Present and future

An overview and an update on the progress achieved in the area of COX inhibitors and their role in health and disease conditions and some unresolved issues related to the use of selective COX-2 inhibitors are discussed.

Evaluating the Cost-Effectiveness of Celecoxib versus Ibuprofen and Naproxen in Patients with Osteoarthritis in United Arab Emirates Based on the PRECISION Trial

From UAE third payer perspective, celecoxib is a long-term cost-effective treatment for osteoarthritis patients when compared with ibuprofen, and equally likely as naproxen to be cost- effective.

Prescribing patterns of celecoxib and prescribers′ perceptions among three general hospitals in Northern Malaysia

The prescribing patterns of celecoxib among the government-subsidized hospitals in Northern Malaysia revealed its high usage in patients without gastrointestinal risk factors and in those with cardiovascular comorbidities may require a review from clinical perspectives.

Comparative safety of NSAIDs for gastrointestinal events in Asia‐Pacific populations: A multi‐database, international cohort study

This work assessed the risk of hospitalization for gastrointestinal events with loxoprofen and mefenamic acid compared with other NSAIDs in Asia‐Pacific populations.

CEOR_A_280556 409..420

From UAE third payer perspective, celecoxib is a long-term cost-effective treatment for osteoarthritis patients when compared with ibuprofen, and equally likely as naproxen to be cost- effective.



A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild-to-moderate osteoarthritis

This review is intended to provide physicians with an overview of the benefits and risks associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in the management of their patients

Update on the management of pain in arthritis and the use of cyclooxygenase-2 inhibitors

  • E. Ross
  • Medicine
    Current pain and headache reports
  • 2009
Chronic pain from arthritis continues to be one of the biggest causes of disability and loss of function in the United States today. This is still the case despite many new insights into the

A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis.

NSAIDs are statistically superior in reducing rest and walking pain compared with acetaminophen for symptomatic osteoarthritis, and Safety, measured by discontinuation due to adverse events, was not statistically different between NSAID- and acetamophen-treated groups.

The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis*

Treatment with rofecoxib was associated with a statistically significantly lower incidence of PUBs than was treatment with NSAIDs, and this analysis demonstrated risk reductions with romethoxib vs. NSAIDs in risk subgroups and in patients who did not have any known risk factors for PPUs consistent with the primary result.

Systematic review of the relative efficacy of non-steroidal anti-inflammatory drugs and opioids in the treatment of acute renal colic

Patients receiving NSAIDs achieve greater reductions in pain scores and are less likely to require further analgesia in the short term than those receiving opioids.

Single dose oral celecoxib for acute postoperative pain in adults.

Single dose oral celecoxib is an effective means of postoperative pain relief and the 400 mg dose has similar efficacy to ibuprofen 400 mg.

Safety of COX-2 Inhibitors in Asthma Patients with Aspirin Hypersensitivity

COX-2 inhibitors provide a potentially safe alternative for treatment of inflammatory conditions in patients with AERD and may be an alternative to aspirin or nonsteroidal antiinflammatory drugs (NSAIDs) in a patient with AerD.

Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond.

  • P. RaoE. Knaus
  • Biology, Medicine
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
  • 2008
This review traces the origins of NSAIDs, their mechanism of action at the molecular level such as cyclooxygenase (COX) inhibition, development of selective COX-2 inhibitors, their adverse cardiovascular effects, and some recent developments targeted to the design of effective anti-inflammatory agents with reduced side effects.

Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?

Cost savings may be achieved by using COX-2 inhibitors in patients at high risk of GI adverse effects even in countries with moderate health care service expenditures.